JPRN-jRCT2080222033未知3 期
Phase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 70age old（—）
- 性别
- All
入选标准
- •1)Medical examination classification: Outpatients
- •2)Observation, examination, and surveillance in accordance with the study protocol are judged to be feasible.
- •3)ETDRS visual acuity test is judged to be feasible at a distance of 4 meters.
- •4)HFA (10-2) test is judged to be feasible by investigator.
- •5)Goldmann perimetry shows concentric central visual field loss (including a ring scotoma) with the central 30 degrees or less.
- •6)The difference in the mean retinal sensitivity at four central points must be less than 3 dB between two measurements with HFA (10-2) conducted within 31 days and both values are worse than 30 dB.
- •(When this criterion is not met after two tests, a 3rd measurement will be implemented.)
排除标准
- •1)Judged to have difficulty by investigator for visiting the hospital and returning home safely over the study period.
- •2)Planning to undergo an ophthalmic operation for eye for efficacy evaluation during study period.
- •3)Current treatment for glaucoma or ocular hypertension.
- •4)Prior ophthalmectomy or evisceration of an eye
- •5)Intraocular surgery within the past five months.
- •6)History of allergy to drugs (instillation narcotics, fluorescein, etc.) that will be used during the clinical study, and to drugs similar to the investigational product
- •7)Complications of diabetic retinopathy.
- •8)Complications of external eye inflammation, infectious diseases, or severe dry eye.
- •9)Use of isopropyl unoprostone in the past or present.
- •10)Use of the following drugs within 31 days before obtaining informed consent.
- •Calcium antagonists, Dark adaptation improvement drug (helenien)
- •11)Participation in UF-021 phase 2 trial (including subjectss assigned to the placebo group).
- •12)Participation in other clinical studies within the past 6 months (However, any subject who has not been administered an investigational product will be accepted)
- •13)Pregnancy or the possibility of becoming pregnant. Currently breastfeeding. Childbearing patients who wish to become pregnant during the clinical study period and are not using appropriate contraceptive measures.
- •14)Cone-rod dystrophy where cone function was primarily impaired
- •15)History of optic nerve disease in the eye for efficacy evaluation
- •16)Complications of a moderate or more severe central cataract, an anterior subcapsular cataract, a posterior subcapsular cataract, and posterior capsule opacification that may exert a major influence on visual acuity in the eye for efficacy evaluation
- •17)History of retinal detachment (including cases that have undergone surgery) or complications of retinal disease that may progress in the eye for efficacy evaluation
- •18)Complications of marked macular oedema (or a cyst), an epimacular membrane or macular traction on the optical coherence tomography (OCT) findings in the eye for efficacy evaluation
- •19)Severe renal disease (blood urea nitrogen: 25 mg/dL or more and/or serum creatinine: 1.5 mg/dL or more), hepatic disease (aspartate aminotransferase [glutamic-oxaloacetic transaminase]) and/or alanine aminotransferase [glutamic-pyruvic transaminase] is 100 U or more), diabetes mellitus with inadequate control, complications of unstable angina, or a history of myocardial infarction
研究者
相似试验
终止
3 期
Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis PigmentosaRetinitis PigmentosaNCT01786395R-Tech Ueno, Ltd.202
已完成
不适用
Visual function after treatment with UF-021 phase2 study in retinitis pigmentosa patientsretinitis pigmentosaJPRN-UMIN000005514Takeshi Sugawara27
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EGFR-Amplified Newly diagnosed glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003171-64-DEAbbVie Deutschland GmbH & Co.KG90
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EUCTR2017-003171-64-NLAbbVie Deutschland GmbH & Co.KG40
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EGFR-Amplified Newly diagnosed glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003171-64-GBAbbVie Deutschland GmbH & Co.KG90